These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 28730474

  • 1. Allosteric Modulation of Src Family Kinases with ATP-Competitive Inhibitors.
    Register AC, Chakraborty S, Maly DJ.
    Methods Mol Biol; 2017; 1636():79-89. PubMed ID: 28730474
    [Abstract] [Full Text] [Related]

  • 2. How ATP-Competitive Inhibitors Allosterically Modulate Tyrosine Kinases That Contain a Src-like Regulatory Architecture.
    Fang L, Vilas-Boas J, Chakraborty S, Potter ZE, Register AC, Seeliger MA, Maly DJ.
    ACS Chem Biol; 2020 Jul 17; 15(7):2005-2016. PubMed ID: 32479050
    [Abstract] [Full Text] [Related]

  • 3. SH2-catalytic domain linker heterogeneity influences allosteric coupling across the SFK family.
    Register AC, Leonard SE, Maly DJ.
    Biochemistry; 2014 Nov 11; 53(44):6910-23. PubMed ID: 25302671
    [Abstract] [Full Text] [Related]

  • 4. Divergent modulation of Src-family kinase regulatory interactions with ATP-competitive inhibitors.
    Leonard SE, Register AC, Krishnamurty R, Brighty GJ, Maly DJ.
    ACS Chem Biol; 2014 Aug 15; 9(8):1894-905. PubMed ID: 24946274
    [Abstract] [Full Text] [Related]

  • 5. Targeting Dynamic ATP-Binding Site Features Allows Discrimination between Highly Homologous Protein Kinases.
    Chakraborty S, Inukai T, Fang L, Golkowski M, Maly DJ.
    ACS Chem Biol; 2019 Jun 21; 14(6):1249-1259. PubMed ID: 31038916
    [Abstract] [Full Text] [Related]

  • 6. Endogenous and synthetic inhibitors of the Src-family protein tyrosine kinases.
    Chong YP, Ia KK, Mulhern TD, Cheng HC.
    Biochim Biophys Acta; 2005 Dec 30; 1754(1-2):210-20. PubMed ID: 16198159
    [Abstract] [Full Text] [Related]

  • 7. C-terminal Src kinase-homologous kinase (CHK), a unique inhibitor inactivating multiple active conformations of Src family tyrosine kinases.
    Chong YP, Chan AS, Chan KC, Williamson NA, Lerner EC, Smithgall TE, Bjorge JD, Fujita DJ, Purcell AW, Scholz G, Mulhern TD, Cheng HC.
    J Biol Chem; 2006 Nov 03; 281(44):32988-99. PubMed ID: 16959780
    [Abstract] [Full Text] [Related]

  • 8. Recent progress of Src SH2 and SH3 inhibitors as anticancer agents.
    Lu XL, Cao X, Liu XY, Jiao BH.
    Curr Med Chem; 2010 Nov 03; 17(12):1117-24. PubMed ID: 20158477
    [Abstract] [Full Text] [Related]

  • 9. Molecular basis for regulation of Src by the docking protein p130Cas.
    Nasertorabi F, Tars K, Becherer K, Kodandapani R, Liljas L, Vuori K, Ely KR.
    J Mol Recognit; 2006 Nov 03; 19(1):30-8. PubMed ID: 16245368
    [Abstract] [Full Text] [Related]

  • 10. Bivalent inhibitors of the tyrosine kinases ABL and SRC: determinants of potency and selectivity.
    Hill ZB, Perera BG, Maly DJ.
    Mol Biosyst; 2011 Feb 03; 7(2):447-56. PubMed ID: 21060940
    [Abstract] [Full Text] [Related]

  • 11. Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src.
    Hari SB, Perera BG, Ranjitkar P, Seeliger MA, Maly DJ.
    ACS Chem Biol; 2013 Dec 20; 8(12):2734-43. PubMed ID: 24106839
    [Abstract] [Full Text] [Related]

  • 12. Active site profiling reveals coupling between domains in SRC-family kinases.
    Krishnamurty R, Brigham JL, Leonard SE, Ranjitkar P, Larson ET, Dale EJ, Merritt EA, Maly DJ.
    Nat Chem Biol; 2013 Jan 20; 9(1):43-50. PubMed ID: 23143416
    [Abstract] [Full Text] [Related]

  • 13. Roles of the SH2 and SH3 domains in the regulation of neuronal Src kinase functions.
    Groveman BR, Xue S, Marin V, Xu J, Ali MK, Bienkiewicz EA, Yu XM.
    FEBS J; 2011 Feb 20; 278(4):643-53. PubMed ID: 21199370
    [Abstract] [Full Text] [Related]

  • 14. ATP-phosphopeptide conjugates as inhibitors of Src tyrosine kinases.
    Nam NH, Lee S, Ye G, Sun G, Parang K.
    Bioorg Med Chem; 2004 Nov 15; 12(22):5753-66. PubMed ID: 15498652
    [Abstract] [Full Text] [Related]

  • 15. Tyrosine Kinase Activation and Conformational Flexibility: Lessons from Src-Family Tyrosine Kinases.
    Meng Y, Pond MP, Roux B.
    Acc Chem Res; 2017 May 16; 50(5):1193-1201. PubMed ID: 28426203
    [Abstract] [Full Text] [Related]

  • 16. A Discovery Strategy for Selective Inhibitors of c-Src in Complex with the Focal Adhesion Kinase SH3/SH2-binding Region.
    Moroco JA, Baumgartner MP, Rust HL, Choi HG, Hur W, Gray NS, Camacho CJ, Smithgall TE.
    Chem Biol Drug Des; 2015 Aug 16; 86(2):144-55. PubMed ID: 25376742
    [Abstract] [Full Text] [Related]

  • 17. Bivalent Inhibitors of c-Src Tyrosine Kinase That Bind a Regulatory Domain.
    Johnson TK, Soellner MB.
    Bioconjug Chem; 2016 Jul 20; 27(7):1745-9. PubMed ID: 27266260
    [Abstract] [Full Text] [Related]

  • 18. Differential sensitivity of Src-family kinases to activation by SH3 domain displacement.
    Moroco JA, Craigo JK, Iacob RE, Wales TE, Engen JR, Smithgall TE.
    PLoS One; 2014 Jul 20; 9(8):e105629. PubMed ID: 25144189
    [Abstract] [Full Text] [Related]

  • 19. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.
    Roskoski R.
    Pharmacol Res; 2015 Apr 20; 94():9-25. PubMed ID: 25662515
    [Abstract] [Full Text] [Related]

  • 20. Novel mechanism of regulation of the non-receptor protein tyrosine kinase Csk: insights from NMR mapping studies and site-directed mutagenesis.
    Shekhtman A, Ghose R, Wang D, Cole PA, Cowburn D.
    J Mol Biol; 2001 Nov 16; 314(1):129-38. PubMed ID: 11724538
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.